Hormone receptor-positive (HR+) breast cancer accounts for approximately 80% of all breast cancer cases [5] and single-agent endocrine therapy is the mainstay for treatment for HR+, human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (e.g., fulvestrant, a selective estrogen receptor). The gene discussed is NR4A1; the disease is breast cancer.